{"id":"NCT02421939","sponsor":"Astellas Pharma Global Development, Inc.","briefTitle":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","officialTitle":"A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-20","primaryCompletion":"2018-09-17","completion":"2025-02-25","firstPosted":"2015-04-21","resultsPosted":"2019-10-17","lastUpdate":"2025-08-29"},"enrollment":371,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia, Acute Myeloid (AML)"],"interventions":[{"type":"DRUG","name":"gilteritinib","otherNames":["ASP2215","XOSPATA®"]},{"type":"DRUG","name":"LoDAC (Low Dose Cytarabine)","otherNames":[]},{"type":"DRUG","name":"Azacitidine","otherNames":[]},{"type":"DRUG","name":"MEC (Mitoxantrone, Etoposide, Cytarabine)","otherNames":[]},{"type":"DRUG","name":"FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)","otherNames":[]}],"arms":[{"label":"Gilteritinib","type":"EXPERIMENTAL"},{"label":"Salvage Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who were refractory to or had relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and determined the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants. This study also determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.","primaryOutcome":{"measure":"Duration of Overall Survival (OS)","timeFrame":"From randomization to until the date of death from any cause (median time of follow-up for OS was 17.8 months)","effectByArm":[{"arm":"Gilteritinib","deltaMin":9.3,"sd":null},{"arm":"Salvage Chemotherapy","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":23},"locations":{"siteCount":126,"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Japan","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["37019445","35130342","35081255","31665578"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":211,"n":246},"commonTop":["Anaemia","Pyrexia","Nausea","Diarrhoea","Alanine aminotransferase increased"]}}